Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits

Journal of Biomolecular Screening

Volumn 15, Issue 7, 2010, Pages 766-782

  Dudgeon, Drew D ^a,b   Shinde, Sunita ^a   Yun Hua, ^a   Tong Ying Shun, ^a   Lazo, John S ^a,b   Strock, Christopher J ^c   Giuliano, Kenneth A ^c   Lansing Taylor, D ^c   Johnston, Patricia A ^c   Johnston, Paul A ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Cellumen Inc   (United States)

Author keywords

anticancer drugs; biosensor; cell based assays; hDM2; high content screening; imaging; p53; protein protein interaction

Indexed keywords

NUTLIN 3; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; ARTICLE; BIOSENSOR; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL LINE; CELL PROLIFERATION; CELL STRAIN HCT116; CYTOTOXICITY; GENE TARGETING; GROWTH INHIBITION; HIGH CONTENT SCREENING; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MOLECULAR LIBRARY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SCREENING; WILD TYPE;

APOPTOSIS; BIOSENSING TECHNIQUES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NAPHTHYRIDINES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; REPRODUCIBILITY OF RESULTS; SMALL MOLECULE LIBRARIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956024383     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110375304     Document Type: Article

References (43)

1. Aylon Y., Oren M.: Living with p53, dying with p53. Cell 2007 ; 130: 597-600.
2. Chipuk JE, Green DR: Dissecting p53-dependent apoptosis. Cell Death Differ 2006 ; 13: 994-1002.
3. Kastan MB, Bartek J.: Cell-cycle checkpoints and cancer. Nature 2004 ; 432: 316-323.
4. Laureline R., Gilles G., Roux P.: Control of cell migration: a tumor supressor function for p53. Biol Cell 2006 ; 98: 141-152.
5. Sengupta S., Harris CC: p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005 ; 6: 44-55.
6. Teodoro JG, Evans SK, Green MR: Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med 2007 ; 85: 1175-1186.
7. Vassilev LT: p53 activation by small molecules: application in oncology. J Med Chem 2005 ; 48: 4491-4499.
8. Voglestein B., Lane D., Levine AJ: Surfing the p53 network. Nature 2000 ; 408: 307-310.
9. Gustafsson B., Stal O.: Overexpression of MDM2 in acute childhood lymphoblastic leukemia. Pediatr Hematol Oncol 1998 ; 15: 519-526.
10. Zhou M., Gu L., Abshire TC, Homans A., Billett AL, Yeager AM., et al. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia 2000 ; 14: 61-67.
11. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B.: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992 ; 358: 80-83.
12. Hu B., Gilkes DM, Chen J.: Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 2007 ; 67: 8810-8817.
13. Hu B., Gilkes DM, Farooqi B., Sebti SM, Chen J.: MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 2006 ; 281: 33030-33035.
14. Toledo F., Wahi GM: MDM2 and MDM4:p53 regulators as targets of anticancer therapy. Int J Biochem Cell Biol 2007 ; 39: 1476-1482.
15. Tovar C., Rosinski J., Filipovic Z., Higgins B., Kolinsky K., Hilton H., et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. PNAS 2006 ; 103: 1888-1893.
16. Wade M., Wong ET, Tang M., Stommel JM, Wahl GM: Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 2006 ; 281: 33036-33044.
17. Wu X., Bayle JH, Olson D., Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993 ; 7: 1126-1132.
18. Bykov VJ, Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002 ; 8: 282-288.
19. Foster BA, Coffey HA, Morin MJ, Rastinejad F.: Pharmacological rescue of mutant p53 conformation and function. Science 1999 ; 286: 2507-2510.
20. Hedstrom E., Issaeva N., Enge M., Selivanova G.: Tumor-specific induction of apoptosis by a p53-reactivating compound. Exp Cell Res 2009 ; 315: 451-461.
21. Vassilev LT, Vu BT, Graves B., Carvajal D., Podlaski F., Filipovic Z., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004 ; 303: 844-848.
22. Wang W., El-Deiry WS: Restoration of p53 to limit tumor cell growth. Curr Opin Oncol 2008 ; 20: 90-96.
23. Wiman KG: Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 2006 ; 13: 921-926.
24. Kussie PH, Gorina S., Marechal V., Elenbaas B., Moreau J., Levine AJ., et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996 ; 274: 948-953.
25. Schon O., Friedler A., Bycroft M., Freund SM, Fersht AR: Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol 2002 ; 323: 491-501.
26. Dmling A.: Small molecular weight protein-protein interaction antagonists: an insurmountable challenge? Curr Opin Chem Biol 2008 ; 12: 281-291.
27. Lai Z., Yang T., Kim YB, Sielecki TM, Diamond MA, Strack P., et al. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci U S A 2002 ; 99: 14734-14739.
28. Murray MF, Jurewicz AJ, Martin JD, Ho TF, Zhang H., Johanson KO., et al. A high-throughput screen measuring ubiquitination of p53 by human mdm2. J Biomol Screen 2007 ; 12: 1050-1058.
29. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef LG, Masucci M., et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004 ; 10: 1321-1328.
30. Bykov VJ, Issaeva N., Zache N., Shilov A., Hultcrantz M., Bergman J., et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 2005 ; 280: 30384-30391.
31. Johnston P., Foster C., Shun T., Skoko J., Shinde S., Wipf P., et al. Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors. Assay Drug Dev Technol 2007 ; 5: 319-332.
32. Johnston PA, Phillips J., Shun TY, Shinde S., Lazo JS, Huryn DM., et al. HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev Technol 2007 ; 5: 737-750.
33. Johnston PA, Foster CS, Tierno MB, Shun TY, Brummond KM, Wipf P., et al. Characterization of the Cdc25B dual specificity phosphatase inhibitor hits identified in a high throughput screen of the NIH compound library. Assays Drug Dev Technol 2009 ; 7: 250-265.
34. Giuliano K., Premkumar D., Taylor D.: Optimal characteristics of protein-protein interaction biosensors for cellular systems biology profiling. In Haney S (ed): High Content Screening: Science, Techniques and Applications. Hoboken, NJ: John Wiley, 2007: 371-387.
35. Johnston P., Soares KM, Shinde SN, Foster CA, Shun TY, Takyi HK., et al. Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug Dev Technol 2008 ; 6: 505-518.
36. Johnston PA, Foster CA, Tierno MB, Shun TY, Shinde SN, Paquette WD., et al. Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library. Assay Drug Dev Technol 2009 ; 7: 250-265.
37. Bansal P., Lazo JS: Induction of Cdc25B regulates cell cycle resumption after genotoxic stress. Cancer Res 2007 ; 67: 3356-3363.
38. Xu B., Kim S., Kastan MB: Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 2001 ; 21: 3445-3450.
39. Wang W., Ho WC, Dicker DT, MacKinnon C., Winkler JD, Marmorstein R., et al. Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol Ther 2005 ; 4: 893-898.
40. Wang W., Takimoto R., Rastinejad F., El-Deiry WS: Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003 ; 23: 2171-2181.
41. Demma MJ, Wong S., Maxwell E., Dasmahapatra B.: CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73. J Biol Chem 2004 ; 279: 45887-45896.
42. Lundholt BK, Heydorn A., Bjorn SP, Praestegaard M.: A simple cell-based HTS assay system to screen for inhibitors of p53-Hdm2 protein-protein interactions. Assay Drug Dev Technol 2006 ; 4: 679-688.
43. Rippin TM, Bykov VJ, Freund SM, Selivanova G., Wiman KG, Fersht AR: Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 2002 ; 21: 2119-2129.